文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.

作者信息

Parrondo Ricardo D, Das Saurav, Sledge Hanna, Bergsagel Leif, Fonseca Rafael, Leung Nelson, Kapoor Prashant, Gertz Morie, Buadi Francis, Dispenzieri Angela, Elliott Jamie, Fernandez Andre, Flott Caitlin, Chanan-Khan Asher A, Roy Vivek, Ailawadhi Sikander

机构信息

Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.

Division of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.

出版信息

Blood Cancer J. 2025 May 23;15(1):100. doi: 10.1038/s41408-025-01310-z.

DOI:10.1038/s41408-025-01310-z
PMID:40410136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12102281/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e52/12102281/6b936535db0f/41408_2025_1310_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e52/12102281/6b936535db0f/41408_2025_1310_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e52/12102281/6b936535db0f/41408_2025_1310_Fig1_HTML.jpg

相似文献

[1]
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.

Blood Cancer J. 2025-5-23

[2]
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.

Oncotarget. 2017-5-16

[3]
The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.

Am J Health Syst Pharm. 2018-1-15

[4]
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.

J Cancer Res Clin Oncol. 2021-1

[5]
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

J Cancer Res Clin Oncol. 2018-12-5

[6]
Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment.

Cureus. 2023-11-23

[7]
Development of [Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.

Eur J Nucl Med Mol Imaging. 2021-5

[8]
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.

Future Oncol. 2025-7

[9]
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.

Onco Targets Ther. 2016-10-5

[10]
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.

Front Oncol. 2025-3-12

本文引用的文献

[1]
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Blood Adv. 2025-3-11

[2]
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

Blood Cancer J. 2024-9-5

[3]
NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

Blood. 2024-9-19

[4]
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.

Leuk Lymphoma. 2024-3

[5]
IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact.

Blood. 2023-7-13

[6]
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma.

Blood Cancer J. 2023-1-11

[7]
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

J Clin Oncol. 2023-1-20

[8]
Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies.

Curr Oncol. 2022-6-23

[9]
How I treat triple-class refractory multiple myeloma.

Br J Haematol. 2022-7

[10]
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

Blood Cancer J. 2020-9-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索